Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.605 USD | +0.17% | +3.00% | -12.88% |
Apr. 18 | Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing | MT |
Apr. 16 | Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.88% | 2.04B | B- | ||
+2.93% | 108B | B+ | ||
+8.82% | 105B | B+ | ||
+2.65% | 23.46B | B | ||
-14.60% | 21.72B | B+ | ||
-7.05% | 18.64B | A- | ||
-38.55% | 17.45B | A- | ||
-8.83% | 17.19B | B | ||
+5.51% | 13.99B | C+ | ||
+37.49% | 12.53B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RXRX Stock
- Ratings Recursion Pharmaceuticals, Inc.